The MNOV chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNOV chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MNOV stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View MNOV Detailed Price Forecast - CNN Money||View MNOV Detailed Summary - Google Finance|
|View MNOV Detailed Summary - Yahoo! Finance||View MNOV Stock Research & Analysis - Zacks.com|
|View MNOV Trends & Analysis - Trade-Ideas||View MNOV Major Holders - Barrons|
|View MNOV Call Transcripts - NASDAQ||View MNOV Breaking News & Analysis - Seeking Alpha|
|View MNOV Annual Report - CompanySpotlight.com||View MNOV OTC Short Report - OTCShortReport.com|
|View MNOV Fundamentals - TradeKing||View MNOV SEC Filings - Bar Chart|
|View Historical Prices for MNOV - The WSJ||View Performance/Total Return for MNOV - Morningstar|
|View the Analyst Estimates for MNOV - MarketWatch||View the Earnings History for MNOV - CNBC|
|View the MNOV Earnings - StockMarketWatch||View MNOV Buy or Sell Recommendations - MacroAxis|
|View the MNOV Bullish Patterns - American Bulls||View MNOV Short Pain Metrics - ShortPainBot.com|
|View MNOV Stock Mentions - StockTwits||View MNOV Stock Mentions - PennyStockTweets|
|View MNOV Stock Mentions - Twitter||View MNOV Investment Forum News - Investor Hub|
|View MNOV Stock Mentions - Yahoo! Message Board||View MNOV Stock Mentions - Seeking Alpha|
|View Insider Transactions for MNOV - SECform4.com||View Insider Transactions for MNOV - Insider Cow|
|View MNOV Major Holdings Summary - CNBC||View Insider Disclosure for MNOV - OTC Markets|
|View Insider Transactions for MNOV - Yahoo! Finance||View Institutional Holdings for MNOV - NASDAQ|
|View MNOV Stock Insight & Charts - FinViz.com||View MNOV Investment Charts - StockCharts.com|
|View MNOV Stock Overview & Charts - BarChart||View MNOV User Generated Charts - Trading View|
The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study
Posted on Wednesday January 09, 2019
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 8) Innoviva Inc (NASDAQ: INVA ) Organogenesis Holdings Inc ...
MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma
Posted on Tuesday January 08, 2019
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first glioblastoma patient has enrolled in the clinical trial of MN-166 (ibudilast) in combination with temozolomide (TMZ, Temodar‑®) for the treatment of recurrent glioblastoma (GBM). The principal investigators are Patrick Y. Wen, M.D., Professor of Neurology, Harvard Medical School and Director, Neuro-Oncology Division at the Dana-Farber Cancer Institute (DFCI) in Boston, and Kerrie McDonald, Ph.D., Associate Professor and Head of Biomarkers and Translational Research at the Lowy Cancer Research Centre, University of New South Wales, Australia.
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan
Posted on Monday January 07, 2019
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of “fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover a composition for inhibiting or treating fibrosis using MN-001 or MN-002.
Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)?
Posted on Wednesday December 12, 2018
If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...